Clinical trial · Interventional
Treatment of a Cancerous Disease of the Peritoneum With Complete Cytoreductive Surgery and Intraperitoneal Chemohyperthermia
Treatment of a Cancerous Disease of the Peritoneum With Complete Cytoreductive Surgery With Intraperitoneal Chemohyperthermia Using Oxaliplatin Plus Irinotecan
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to evaluate the treatment of a cancerous disease of the peritoneum with complete cytoreductive surgery with intraperitoneal chemohyperthermia using oxaliplatin plus irinotecan. This is a Phase II study with 100 patients. Origins of the tumors: these include colon, rectum, appendix, peritoneum, and endocrine tumors.
Conditions
Conditions (5)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Appendix Tumors | Appendix Neoplasm | ALIAS | 0.90 |
| Colon Tumors | Colon Neoplasm | ALIAS | 0.90 |
| Endocrine Tumors | Endocrine Neoplasm | ALIAS | 0.90 |
| Peritoneum Tumors | — | UNRESOLVED | — |
| Rectum Tumors | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Oxaliplatin and irinotecan | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- To study overall survival
Secondary outcomes (1)
- measure
- To study mortality-morbidity
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 65 Years
Show eligibility criteria text
Inclusion Criteria: * Peritoneal seedings coming from colon, rectum, pseudomyxoma (appendix), peritoneum (mesothelioma and serous tumors), or endocrine tumors. * No extra-abdominal metastases * Good general status (American Society of Anesthesiologists Physical Status score \[ASA\] 1 or 2) * Signed consent Exclusion Criteria: * Tumor seedings coming from other origins * Huge peritoneal carcinomatosis (peritoneal score \> 25, except for pseudomyxomas) * Peritoneal carcinomatosis progressing rapidly * Presence of extra-abdominal metastases * Patients presenting contraindications to the use of oxaliplatin or irinotecan
References
Publications (0)
Data not yet available